










The Centre for Health Economics Research and Evaluation (CHERE) was 
established in 1991.  CHERE is a centre of excellence in health economics and 
health services research. It is a joint Centre of the Faculties of Business 
and Nursing, Midwifery and Health at the University of Technology, Sydney, in 
collaboration with Central Sydney Area Health Service. It was established as a 
UTS Centre in February, 2002. The Centre aims to contribute to the development 
and application of health economics and health services research through 
research, teaching and policy support. CHERE’s research program encompasses 
both the theory and application of health economics. The main theoretical 
research theme pursues valuing benefits, including understanding what 
individuals value from health and health care, how such values should be 
measured, and exploring the social values attached to these benefits. The 
applied research  focuses on economic and the appraisal of new programs or new 
ways of delivering and/or funding services. CHERE’s teaching includes 
introducing clinicians, health services managers, public health professionals 
and others to health economic principles. Training programs aim to develop 
practical skills in health economics and health services research. Policy 
support is provided at all levels of the health care system by undertaking 
commissioned projects, through the provision of formal and informal advice as 
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The aims of this paper are: to review and describe different approaches to HTA used in 
Australia and in other countries and to identify the features of best practice in HTA, 
particularly those likely to be most relevant to HTA at a local (ie state/regional) level. 
 
There are a number of well-developed models of HTA at the national and local levels. 
Most information about the operation of these models, particularly about the type and 
number of evaluations conducted, the recommendations/decisions made and the 
reasons for these is available for national processes, but there is much less readily 
available documentation about local level HTA. Most HTA processes that operate 
nationally and internationally can be categorised in one of three ways: guidance 
(provides structured information about appropriate technologies), mandatory (provides 
mandatory information about technologies to be implemented) and funding and 
implementation (provides structured evidence-based advice about which technologies 
should be implemented, the level of funding required to implement them and the source 
of these funds). 
 
The main factors which distinguish a high quality HTA process are that i) it is efficient in 
terms of setting priorities, the scope of the technologies to be assessed, avoidance of 
duplication and overall cost of the process, ii) the overall impact on utilisation and health 
budget is calculated as part of the HTA and iii) procedural justice occurs and is seen to 
occur; iv) it includes a comprehensive assessment of the impact on issues such as 
workforce, credentialing of providers and the ethical dimension of the technology; v) it 
influences decision making by being communicated appropriately and using trusted 
methods; vi) it influences adoption and diffusion of technology by ensuring that there is 
no diffusion prior to HTA, the results are incorporated into guidelines or 
recommendations, funding is linked to the decision, and remuneration arrangements and 
other characteristics of the HS facilitate the appropriate adoption and diffusion and vii) it 
influences health outcomes/efficiency/equity by ensuring that the methods and/or results 
are available and able to be used at a local level. 
 
Firm recommendations for an ideal system for HTA at the local level are not possible as 
much of the necessary information and evidence is not available about the strengths and 
weaknesses of HTA practices and processes currently in use. However, it is likely that 
the operation of a successful model of HTA at a local level would require the 
development of a central organizational unit, a process for implementing the results of 
HTA and, crucially, the building of capacity to support both types of activities. Additional 
expertise and skills will be required for both providers of HTA evaluations and for the 
commissioners and users of HTA. 
  
Introduction 
The challenge for health technology assessment (HTA) is to create policies that 
harness the benefits of technology and innovation while not encouraging the use 
of interventions for which the additional benefits are not worth their costs. The 
balance of benefits and costs has to be attained within a health system which has 
multiple objectives and complex funding and financing arrangements, where 
consumers do not face the full costs of services. Health technologies are 
considered by many to be a key driver of increasing health care costs in 
developed countries. HTA is broad in both its methods and applications. It can 
encompass assessments of safety, efficacy, effectiveness, cost, cost-
effectiveness, as well as organisational, social, ethical and legal implications and 
be applied to drugs, devices, procedures and the organisational and support 
systems within which health care and health services are delivered (Busse, 
Orvain et al. 2002); it can encompass existing as well as new or emerging 
technologies.  
 
HTA relies on the available research evidence. While it may develop new 
syntheses, including new decision analytic models, it does not conventionally 
include the generation of new primary research in the form of clinical trials or 
other studies.  The purpose of HTA is to enhance efficient health care resource 
allocation, so the assessment of best practice in HTA must consider the impact of 
the process on subsequent technology diffusion. 
 
HTA methods have been developed over a considerable period of time. In its 
earliest phase, many assessments were largely an academic exercise with 
outputs measured in journal publications. More recently, incentives for HTA 
evidence in policy formulation, particularly funding reimbursement, have been 
introduced. In most countries, these have taken the form of a regulatory hurdle, 
i.e. regulation has required the assessment of safety, effectiveness and cost-
effectiveness as a precursor to marketing or funding approval.  
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Cost-effectiveness and other economic evaluation techniques address the 
question of efficient allocation of resources within a budget constraint.  However, 
in most centralized approaches to HTA the budget constraint is not evident, so 
that it is not clear what alternative use of resources, and resulting health gains, 
will be foregone. Consequently, HTA evaluators and decision makers have 
tended to rely on an implicit shadow price; for example, interventions that have 
an incremental cost-effectiveness ratio (ICER) of $70,000 per QALY or less may 
be seen as a good buy. It should also be noted that the use of a shadow price 
may or may not be explicit in the decision making process.  
 
At a local level where budgets are defined, the opportunity cost should be 
clearer. This provides both an incentive and a disincentive for HTA. The incentive 
is that as the opportunity cost is explicit, and the budget constraint more binding, 
the gain in efficiency by applying HTA should be greater. The disincentive is that 
although the budget constraint is clear, the application of the technology is set 
within a context where differences in patient characteristics, disease severity, and 
the extent of uncertainty, lessen the precision of any ICER. At the same time, 
individual opinion leaders can be expected to hold greater sway, and there are 
peer pressures to ensure co-operative behaviour, particularly where authority and 
command structures are not defined.  For these reasons, it is not surprising that 
HTA has proved more difficult to establish at local levels and may be less 
influential in decisions even when it has taken place. 
 
Much of the international literature published on HTA is focussed at a national 
level (Lehoux, Denis et al. 2005);(Medical Services Advisory Committee 2005); 
(Organisation for Economic Co-operation and Development. 2005). It is much 
less clear how HTA could be operationalised at a more local level. The aims of 
this paper are: to review and describe different approaches to Health Technology 
Assessment (HTA) used in Australia and in other countries (section 2); to identify 
the features of best practice in HTA (section 3); and to use the evidence so 
generated to outline a model which is relevant to more local jurisdictions which 
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have responsibility for the delivery of health services in Australia such as state 
health systems, area/regional health services or hospital networks (section 4).  
Overview of current HTA processes 
The best known HTA processes are those which are co-ordinated at a national 
level, often linked to national funding programs, and often widely promoted as 
exemplars by those involved. These include the National Institute for Health and 
Clinical Excellence (NICE) in England and Wales, the Canadian Agency for 
Drugs and Technologies in Health (CADTH) and New Zealand’s PHARMAC, plus 
in Australia, the Pharmaceutical Benefits Advisory Committee (PBAC) and the 
Medical Services Advisory Committee (MSAC).  
In a number of other countries with more fragmented funding programs, such as 
Canada, Spain and the United States, health technology assessment is 
undertaken at the funding agency level which might be a state/provincial health 
authority or a health insurer level. (Perry and Thamer 1997; The Canadian 
Agency for Drugs and Technologies in Health (CADTH) 2007) Canada has an 
extensive network of federal and regional organisations including nine major 
agencies/units. Spain has six regional agencies and in 1997 53 HTA agencies 
were operating in the United States (Perry and Thamer 1997).  
Table 1 provides a summary of HTA processes in use at the national level in 
Australia (Australian Government. Department of Health and Ageing 2006); 
(Medical Services Advisory Committee 2005) and Canada (Canadian Agency for 
Drugs and Technologies in Health 2006); (The Canadian Agency for Drugs and 
Technologies in Health (CADTH) 2007), at the provincial level in one Canadian 
province, Ontario (Ontario Ministry of Health and Long-Term Care 2007) and one 
Australian State, Victoria (Victorian Department of Human Services 2006), and at 
a more local level in Sweden (Ostergotlund) (The Danish Centre for Evaluation 
and Health Technology Assessment 2005),Victoria (Southern Health Area, 
Melbourne) (Southern Health 2001) and New South Wales (New South Wales 
Health Department 2003). 
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Table 1 shows that there are a number of well-developed models of HTA at the 
national and local levels. Information about the operation of individuals models, 
particularly about the type and number of evaluations conducted, the 
recommendations/decisions made and the reasons for these is available for 
national processes, but there is much less readily available documentation about 
local level HTA. This limits the extent to which success and the features of best 
practice of HTA at a provincial or more local level can be judged. Nonetheless, it 
is likely that some features of best practice can be generalised to apply to local 
models. Further it seems that more consideration could be given to how national 
models can provide an information base for more local models, rather than 
categorising the two approaches as independent alternatives. 
While HTA is broad in its scope, models vary across different HTA processes. 
While the most comprehensive cover all health services, many if not most models 
restrict their scope to procedures only, drugs only, or services requiring major 
capital items.  In general, it seems that the approaches developed for drugs are 
more well-established and systematic than for other technologies. This is not 
surprising given the relatively simple nature of drugs (e.g. in terms of delivery and 
investigation of outcomes) compared to other technologies and the well 
developed and funded system of company-sponsored clinical trials which leads 
to more and better evidence being available for the HTA process.  
Models also vary according to the process by which technologies are considered 
and prioritised for HTA. Some models are pro-active, determining priorities by a 
mix of seeking emerging issues and horizon scanning for new technologies; 
others are reactive and rely on submissions, often from interested parties.  
All the models of HTA described in Table 1 except that in use in Ontario, Canada, 
were limited to the synthesis of existing evidence, and were not set up to 
generate new evidence or to fund new research. Therefore, where the evidence 
is inconclusive, there is little available to influence the funding and conduct of 
new research beyond moral persuasion and wishing. This is a limitation of 
existing models. However, some models do allow for the implementation and 
  8 
impact of their recommendations to be monitored. Further, for any specific 
technology/condition, there is generally limited research evidence, particularly 
published randomised controlled trials. As all models draw on the same evidence 
there may be inefficiencies in having the same HTA repeated a number of times 
in different countries and jurisdictions. Yet it is possible for different processes to 
result in different recommendations, in part because the context and current 
alternative can vary form setting to setting. For example, the recommendation in 
relation to Herceptin® for early stage breast cancer, differ considerably across 
different countries - it has been funded in Australia and rejected in New Zealand 
(Barrett, Roques et al. 2006); (Breast Cancer Network Australia 2007). The 
increasing formalisation of HTA sets up new pressures to introduce new 
technologies based on their adoption in other countries, as advocates question 
the need to repeat HTA analyses.  
A lack of explicit budgetary constraints is a problem for all national processes. 
The use of a shadow price for a unit of health gain does not mean that this ratio 
of marginal benefit to marginal cost will be achieved in practice. Further, the use 
of one shadow price rests on a number of assumptions, most importantly, a 
constant and divisible marginal social value of a health gain. For the more local 
HTA processes a budgetary constraint is more likely to be explicit. But it is not 
clear that the models we have identified take these into account, and if so what 
type of economic analysis was most useful. Nor were we able to assess the 
extent to which decisions made as a result of HTA have been implemented. 
This review suggests that three general categories can be used to describe most 
HTA processes that operate nationally and internationally. To a large extent, 
these can describe local area processes also. For example, although funding and 
implementation models are commonly conducted at a centralised level, they 
could also be adopted at a local level. 
•  Guidance: HTA may be conducted at a centralised or a relatively 
decentralised level in the system to provide structured evidence-based advice 
about which technologies are appropriate and should be implemented (and 
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may provide advice about technologies that should not be used or should be 
stopped). However in this model there is no explicit mechanism for the 
guidance to be implemented.  The Common Drug Review in Canada is an 
example of this approach (The Canadian Agency for Drugs and Technologies 
in Health (CADTH) 2007); (Mitton, McMahon et al. 2006).  
•  Mandatory: HTA may be conducted at a centralised or decentralised level in 
the system to provide structured evidence-based advice about which 
technologies must be implemented (and may provide advice about which 
technologies must not be used). In this model the advice is mandatory – there 
is a requirement for health service managers to implement the decisions and 
for providers to abide by the guidance. However, there is no explicit flow of 
funds attached to the recommendations, and therefore no explicit assessment 
of the financial or health services utilisation impacts of the recommendations. 
In particular, this has implications for what activities must be forgone to 
implement new technologies when there is no additional funding to support 
the recommendation.  NICE is an example of this approach (Raftery 2006).  
•  Funding and implementation: HTA is conducted at a centralised level in the 
system to provide structured evidence based advice about which technologies 
should be implemented, the level of funding required to implement them and 
the source of these funds. The implication of this model is that there is a direct 
link between the HTA process and the implementation, via an identified 
source of funds. Most often this explicitly recognises that implementation of 
new technologies is likely to be expansionary for the health budget. Ideally 
such a model should allow for assessment of the social costs and benefits of 
this increase in funding. PBAC and MSAC in Australia are examples of this 
approach (Australian Government. Department of Health and Ageing 2006); 
(Medical Services Advisory Committee 2005).  
Clearly there are many variations to these three broad categories, and particular 
models adopted may not fit neatly into one category. For example, the funding 
mechanism may vary. 
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Features of Best Practice in HTA 
Table 2 identifies the features used to describe the different HTA processes and 
the means by which the quality of the process can be judged. This makes clear 
that there are certain aspects that are common across the various models of HTA 
and others that are unique to particular models.  
The features of HTA which would guarantee a high quality process as well as 
ensuring that decisions made on the basis of the HTA process are as well-
informed as possible are summarised in the Box. 
Box: Features of a high quality HTA process 
 
•  the process for conducting HTA is efficient in terms of setting priorities, 
the scope of the technologies to be assessed, avoidance of duplication 
and overall cost of the process; 
•  the overall impact on utilisation and health budget is calculated as part 
of the HTA; 
•  procedural justice occurs and is seen to occur as evidenced by: 
o  Robustness in technical evaluation (free from political influence) 
Leverage/authoritative in health system/authority. (e.g. NICE) 
o Transparency 
•  it includes a comprehensive assessment of the impact on issues such 
as workforce, credentialing of providers and the ethical dimension of 
the technology; 
•  it influences decision making by being communicated appropriately and 
using trusted methods; 
•  it influences adoption and diffusion of technology by ensuring that there 
is no diffusion prior to HTA, the results are incorporated into guidelines 
or recommendations, funding is linked to the decision, and 
remuneration arrangements and other characteristics of the HS 
facilitate the appropriate adoption and diffusion; and 
•  it influences health outcomes/efficiency/equity by ensuring that the 
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A model of HTA relevant to local jurisdictions in Australia 
Firm recommendations for an ideal system for HTA at the local levels are not 
possible as much of the information and evidence is not available about the 
strengths and weaknesses of HTA practices and processes currently in use. 
However, it is likely that the operation of a successful model of HTA at local 
levels would require the development of both a central organizational unit and a 
process for implementing the results of HTA and, crucially, the building of 
capacity to support both types of activities. Additional expertise and skills will be 
required for both providers of HTA evaluations and for the commissioners and 
users of HTA. 
 
The functions of a state/provincial-based unit would include building capacity in 
HTA, supporting local initiatives by providing access to high level expertise and 
coordinating current and future HTA activities at both provincial and local levels. 
Coordination would encompass a number of activities. First, it would be 
necessary to develop priorities for HTA, identify developing technologies and 
develop priorities for assessment and identification of technologies which are 
becoming ineffective and obsolete. This function would be strengthened by 
providing a capacity to generate or at least influence new research, so that the 
information base for HTA was improved. Second, it would be important to 
develop a process by which decisions are made about which technologies are 
best assessed at a state/provincial level and which should be undertaken at a 
more local level. Third, it would be essential to develop processes that are 
efficient (ie avoided duplication, set priorities that reflect the needs at both 
provincial and more local levels), ensure procedural justice in terms of 
undertaking or commissioning high quality, independent evaluations and enabling 
the decision making processes to be transparent and authoritative. Finally, the 
expertise available at this level would be needed to assist local decision makers 
to translate the results of national- or provincial-level assessments to the 
appropriate level. This means developing the means to take into account the 
impact of the introduction of a technology on the population of a particular 
  12 
geographical area (given the health and socio-demographic characteristics of the 
population), its workforce and budget. 
 
A successful HTA process must also include a well-developed implementation 
process. First, decisions about which technologies should be implemented must 
be linked to the level of the health system that holds the responsibility for the 
budget. Without the right incentives in place, the introduction of technologies will 
be patchy, possibly resulting in inequity. Second, incentives should be aimed at 
encouraging active participation in the process of HTA in such a way that 
emphasis is placed on the provision of evidence about the technology under 
review. This will ensure that the outcome of the HTA process overall is evidence 
about the efficient use of resources. Third, it must be recognized that successful 
implementation will not occur unless accompanied by additional funding. 
However, it may be possible to obtain some additional funds through the removal 
from use of ineffective or obsolete technologies. Finally, ineffective and/or 
obsolete technologies should be discontinued and this should be taken into 
account in the determination of budgets.  
 
It is likely that some HTA will need to be undertaken at a local (ie local 
administrative or hospital) level. Although evidence about best practice in HTA at 
this level is limited, it is likely to be most useful when technologies are being 
considered which seem likely to have a differential impact depending on the 
characteristics of the population (and therefore likely to be more or less efficient 
in different localities), where there are major implications regarding workforce 
issues (eg availability of particular types of clinicians, or the need for 
credentialing) or where consideration is being given to the expansion of a 
technology from one level of the health services another (eg from a tertiary to a 
district hospital). 
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Conclusion 
HTA is relatively well-developed at a national level in Australia. However, given 
that most health care services are planned, funded and delivered at the provincial 
and more local levels, there is scope for the processes of HTA to be developed 
more fully at these levels, creating advantages beyond those produced by current 
national processes. A comprehensive assessment of the impact of the 
introduction of the technology would be possible, including estimation of the 
overall impact of the technology on utilisation and the health budget. Issues such 
as workforce, credentialing of providers and the ethical dimension of the 
technology would be able to be taken into account. Health outcomes, efficiency 
and equity would be positively influenced by ensuring that the methods and/or 
results were available and able to be used at a local level. Finally, the potential 
would be developed for the results of HTA undertaken at both levels to be fed 
into an “information loop”.  If developed successfully and implemented in a 
rigorous fashion, such a loop would enable “good” variation in terms of patterns 
of practice to be distinguished from “bad” variation. For example, it should be 
possible to distinguish between inequitable levels of care occurring as a result of 
where an individual resides versus acceptable variation which occurs in response 
to individual or local circumstances. 
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Table 1 Summary of selected HTA processes at national, state/provincial and local levels 
  Scope HTA  process  Outcomes  Limitations 
National 
NICE (UK)  All technologies  Work commissioned by Dept. of 
Health. 
Systematic review + economic 
analysis. 
Undertaken by independent 
advisory bodies. 
Ineffective practice review (under 
development) 
Mandatory recommendations for 
adoption. Budgetary implications 
estimated. 
No budgetary responsibility = no 
financial constraints. 
Regional inconsistencies persist 
CADTH 
(Canada) 
All technologies  Topics identified though horizon 
scanning + independent 
proposals. Topics prioritised bi-
annually. 
Effectiveness, economic 
evaluation, implementation, policy 
& health services impact. 
Recommendations in the form of 
advice. 
No enforcement of 
recommendations. Participation in 
process by provinces is voluntary. 
No links to funding. 
No means of ensuring that 
findings inform provincial 
decisions. 
PBAC (Australia)  Pharmaceuticals   Sponsor prepares application 
(following guidelines). 
Effectiveness, cost-effectiveness, 
clinical benefit, availability of 
alternative treatment.  
Applications independently 
reviewed. 
Recommendations for listing on 
the schedule (PBS). 
Recommendations re indications. 
Other restrictions can be imposed. 
Applications “commercial-in 
confidence” 
Brief statement of justification only 
Negotiations re price not part of 
the process 










Applications reviewed under 
direction of the committee. 
Recommendations for listing on 
the schedule (MBS). 
May also reject, recommend 
public or interim funding 
Full report published 
Directly determines scheduled 
payments to medical practitioners. 
Indirectly determines payment for 
all procedure costs. 
No independent review 
May use non-trial evidence 
Open-ended program 
Interim funding may discourage 
research on long-term outcomes. 
Provincial/State 
OHTAC  Procedures,  Meets once a month  Preliminary assessment used to  Recommendations not mandatory 





Topics proposed by any publicly 
funded health facility in Ontario. 
Topics prioritised using algorithm 
Preliminary assessment  
Full assessment by experts 
including industry. 
Efficacy, safety, effectiveness, 
cost-effectiveness, budget impact, 
workforce implications. 
May request additional data be 
collected via field evaluations. 
make recommendation or request 
full assessment. 
Recommendations + full analysis 
posted on website 







Meets up to 4 times/year 
Submission must be completed for 
each technology/practice for which 
funding is requested. 
Collaboration required for proposal 
involving same 
technology/practice 
Clinical experts &/or time-limited 
panels may be involved. 
Details not publicly available.  Criteria used to make 
assessments not clear 
Outcomes & justification not 
available publicly 
Not clear whether its role is that of 
peek advisory body or body 







Methods Board  
Aims to identify & evaluate 
technologies important to local 
services, make decisions about 
introducing/repealing 
technologies. 
Short summary report including 
recommendations to inform the 
decisions of the county council. 
Role not clear 
Criteria used to make 
assessments not clear 







New Clinical Procedures 
Committee 
Aims to assess introduction of new 
technologies at all levels of system 
Staff trained to use technologies 
safely & to high standard 
Application prepared by senior 
clinician, approved by senior 
management, submitted to NCPC 
Efficacy, safety, costs & benefits  
First approval for 12 months 
Written report re experience & 
benefits of new technology 
Not clear what range of 
technologies is considered 
Outcomes & justification not 
available publicly 
Not clear about outcomes once 
the written report is received. 








No production of HTA evidence in 
the form of comparative 
assessment of safety, 
effectiveness and cost-
effectiveness. Evaluations 
conducted elsewhere may be 
reported. Appraisal and decision 
making delegated to AHS level 
No information available  Explicitly excludes interventions 
new to the State for which it is 
expected there will be a 
centralised process for 
determining safety, effectiveness 
and appropriateness (cost-
effectiveness not explicitly 
discussed). Not clear what the 
centralised process is or whether it 
has been implemented 
 
Table 2. Key attributes of HTA  
Attribute  Description  Measures of best practice 
HTA Priority 
Setting 
Who sets priorities for assessment? 
What is the process for setting 
assessment priorities, including any 
horizon scanning 
Short time between innovation and assessment 
High impact technologies prioritised 
Assessment conducted before adoption/diffusion 
HTA/Technology 
scope 
What types of technologies are 
assessed? 
Broad definition of technology that includes: 
•  Old and new technologies, 
•  All health related technologies   (drugs, procedures, services) 
•  Can be disease-based 
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HTA Production  Who does it?  
Who funds it?  
Timelines? 
Assessment is: 
1.  of high quality and highly regarded 
2. produced  efficiently 
3.  in line with decision making timeframe 
HTA Evidence  What level of evidenced is 
used/rejected? 
How is evidence merged?  




Comprehensive inclusion of evidence but appraisal of rigour and quality 
HTA Content  What issues are covered? Safety/quality; 
efficacy, effectiveness, cost-
effectiveness, total cost, utilisation, 
ethics, equity, incentives, risks, 
uncertainty 
Comprehensive and broad 
HTA Quality 
Assurance 
What processes are in place to ensure 
that HTA content is of high quality? 
Evidence of impact of the quality assurance process 
HTA Appraisal  Who makes the final recommendation?  
How are the trade-offs between impact 
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How prescriptive is the HTA appraisal 
recommendation? 
Does appraisal take funding issues into 
account/allocative efficiency?  
Economic analysis includes – budget impact, societal perspective, service delivery 
issues including induced demand for use of equipment, crowding out of existing 
services, workforce – supply and training 
Basis for decision explicit 
HTA 
Dissemination 
Who is the target audience 
What strategies are used to disseminate 
the results of HTA? 
HTA activities/results are widely known amongst target audience 
Decision-making 
process 
Who is involved?  
At what level of the health care system 
are resource allocation decisions made? 
Adherence to notions of procedural justice (e.g. accountability for reasonableness 
framework) 
Are the appropriate decisions made at the appropriate level?  
Decision 
implementation 
How do decision-makers implement 
recommendations?  
What incentives are available to 
support decision implementation?  
How can decision-makers deal with 
uncertainty 
Diffusion in line with HTA recommendations 
Prevents diffusion prior to HTA 
Feedback into primary research  
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